文献速递淋巴瘤

合并症对老年外周T细胞淋巴瘤患者的影响:891例国际回顾性分析

Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients.
PubMed 文献 · Blood Adv · 2022-01-01

该国际回顾性队列纳入瑞典淋巴瘤登记处和加州癌症登记处2010至2015年诊断的≥70岁外周T细胞淋巴瘤患者891例,按Charlson合并症指数(CCI)分组。CCI>1组中位总生存仅4.4个月,差于CCI=0组的11.9个月和CCI=1组的8.4个月(P<.001),多数患者在诊断后一年内死于淋巴瘤。

要点

  • 老年PTCL患者中CCI>1者中位OS仅4.4个月,显著劣于CCI=0的11.9个月。
  • 合并症与年龄每增加5岁均为该人群的重要不良因素。
  • 多数患者诊断后一年内死于淋巴瘤,亟需开发新治疗。

核心结论

  • 在≥70岁外周T细胞淋巴瘤患者中,合并症负担重(CCI>1)与更差的中位总生存相关。
  • 合并症和年龄以5岁递增均为该人群的重要不良因素。
  • 多数患者诊断后一年内死于淋巴瘤,提示需要开发新治疗方法。

研究设计与样本

  • 国际回顾性队列研究,纳入瑞典淋巴瘤登记处(SLR,n=173)和加州癌症登记处(CCR,n=718)2010年1月1日至2015年12月31日诊断的≥70岁PTCL患者,共891例。
  • 合并症数据按Charlson合并症指数(CCI)回顾性收集,775例(87%)有CCI数据。
  • CCI分组为CCI=0(39%)、CCI=1(22%)、CCI>1(39%),各组中位年龄无差异(P=.72)。

主要发现

  • SLR中位年龄77岁,CCR中位年龄78岁。
  • 纳入亚型包括:血管免疫母细胞性T细胞淋巴瘤n=226、间变性大细胞淋巴瘤n=122、肠病相关T细胞淋巴瘤n=31、肝脾T细胞淋巴瘤n=7、NK/T细胞淋巴瘤n=62、PTCL非特指型n=443。
  • CCI>1组中位总生存4.4个月,CCI=1组8.4个月,CCI=0组11.9个月(P<.001)。

临床怎么用

  • 对≥70岁PTCL患者应评估合并症(CCI),CCI>1提示预后极差,可辅助治疗决策与预后沟通。
  • 合并症负担重且高龄患者生存期短,多数一年内死于淋巴瘤,提示需优先考虑新治疗策略。

局限性

  • 为回顾性研究,合并症数据按CCI回顾性收集,775例(87%)有CCI数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive neoplasms with poor outcomes, commonly affecting older patients with comorbidities. This study aims to describe outcomes of older patients with PTCL in a large international cohort. Patients aged ≥70 years with PTCL diagnosed from 1 January 2010 to 31 December 2015 in the Swedish Lymphoma Registry (SLR) and California Cancer Registry (CCR) were identified. Data on comorbidity were retrospectively collected according to the Charlson Comorbidity Index (CCI), and clinical outcomes were extracted. A total of 891 patients were included (SLR, n = 173; CCR, n = 718). Median age was 77 (SLR) and 78 (CCR) years. Included subtypes were as follows: angioimmunoblastic T-cell lymphoma, n = 226; anaplastic large-cell lymphoma, n = 122; enteropathy-associated T-cell lymphoma (EATL), n = 31; hepatosplenic TCL, n = 7; natural killer-/T-cell lymphoma, n = 62; PTCL not otherwise specified, n = 443. CCI data were available in 775 patients (87%), and CCI scores were divided into the groups CCI = 0 (39%), CCI = 1 (22%), and CCI > 1 (39%). Median age did not differ among the CCI groups (P = .72). Patients with a CCI > 1 had a worse median overall survival (4.4 months) compared with patients with CCI = 0 (11.9 months) and CCI = 1 (8.4 months; P < .001). Comorbidity and advancing age in as little as 5-year increments are important adverse factors in this group. Most patients died of lymphoma within a year from diagnosis, underscoring the importance of developing new treatments.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mead M, Cederleuf H, Björklund M, et al. Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients. Blood Adv. 2022. PMID: 34570186. doi:10.1182/bloodadvances.2021004269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。